OncoMatch

OncoMatch/Colorectal Cancer (CRC)/MSH2

Colorectal Cancer (CRC)MSH2 Clinical Trials

36 recruiting trials·Updated daily from ClinicalTrials.gov

MSH2 is one of four mismatch repair proteins assessed by IHC; loss of MSH2 defines deficient MMR (dMMR) and predicts MSI-H status, qualifying patients for checkpoint immunotherapy. dMMR CRC responds dramatically to PD-1 blockade — pembrolizumab is first-line standard for dMMR metastatic CRC. Trials explore neoadjuvant immunotherapy, combination checkpoint approaches, and MSI as a predictive biomarker across treatment lines.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting MSH2 Colorectal Cancer (CRC) trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 2/Phase 3

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Centre Hospitalier Universitaire de Besancon

Phase 3

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Jun Huang

Phase 2/Phase 3

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Sun Yat-sen University

Phase 3

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Sun Yat-sen University

Phase 2/Phase 3

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 3

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

National Cancer Institute, Naples

Additional trials

More MSH2 Colorectal Cancer (CRC) trials

See all in search →
Phase 2
NCT06792695A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerPhase 214 US sitesNCT05592626A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsPhase 1/Phase 213 US sitesNCT04165772Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsPhase 210 US sitesNCT06992258A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerPhase 29 US sitesNCT06529523Tislelizumab in People With Colorectal CancerPhase 21 US siteNCT06959550Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerPhase 21 US siteNCT05411718A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch SyndromePhase 21 US site
17 international trials (no US sites)
NCT06923345Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)Phase 2NCT06567782A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerPhase 2NCT04920149Mesalamine for Colorectal Cancer Prevention Program in Lynch SyndromePhase 2NCT06856837- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesPhase 2NCT07347951A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal CancerPhase 2NCT06698757Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal CancerPhase 2NCT06911684Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.Phase 2NCT05462236MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal CancerPhase 2NCT05771181Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsPhase 2NCT06580574Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersPhase 2NCT07068763Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal CancerPhase 2NCT06002789Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCCPhase 2NCT06722183Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor EntitiesPhase 2NCT05954429A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyPhase 2NCT07279077Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II TrialPhase 2NCT05310643Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCPhase 2NCT06949111Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）Phase 2
Other Colorectal Cancer (CRC) biomarkers

Browse other molecular targets with active Colorectal Cancer (CRC) trials.

KRASNRASBRAFMMR / MSI-HMSH6PMS2MLH1HER2 (ERBB2)EGFR
← All Colorectal Cancer (CRC) clinical trials